These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30926356)

  • 1. Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.
    Nakamura M; Kageyama SI; Niho S; Okumura M; Hojo H; Motegi A; Nakamura N; Zenda S; Yoh K; Goto K; Akimoto T
    Clin Lung Cancer; 2019 May; 20(3):e256-e264. PubMed ID: 30926356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
    Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS
    Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
    Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
    Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy.
    Lim YJ; Chang JH; Kim HJ; Keam B; Kim TM; Kim DW; Paeng JC; Kang KW; Chung JK; Jeon YK; Chung DH; Wu HG
    Clin Lung Cancer; 2017 May; 18(3):e169-e178. PubMed ID: 28131636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
    Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.
    Hayashi H; Okamoto I; Kimura H; Sakai K; Nishimura Y; Nishio K; Nakagawa K
    Anticancer Res; 2012 Oct; 32(10):4533-7. PubMed ID: 23060582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer.
    Mori M; Hayashi H; Fukuda M; Honda S; Kitazaki T; Shigematsu K; Matsuyama N; Otsubo M; Nagayasu T; Hashisako M; Tabata K; Uetani M; Ashizawa K
    Thorac Cancer; 2019 Apr; 10(4):872-879. PubMed ID: 30811109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy].
    Li F; Bai H; Li X; Wu M; Yu R; Shi A; Yin L; Wang J; Zhu G
    Zhongguo Fei Ai Za Zhi; 2011 Sep; 14(9):715-8. PubMed ID: 21924037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
    Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
    Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.
    Chaft JE; Dagogo-Jack I; Santini FC; Eng J; Yeap BY; Izar B; Chin E; Jones DR; Kris MG; Shaw AT; Gainor JF
    Lung Cancer; 2018 Aug; 122():67-71. PubMed ID: 30032847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis.
    Kim H; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
    Cancer Res Treat; 2023 Apr; 55(2):498-505. PubMed ID: 36228655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-small cell lung cancer in the very young: Higher EGFR/ALK mutation proportion than the elder.
    He CH; Shih JF; Lai SL; Chen YM
    J Chin Med Assoc; 2020 May; 83(5):461-465. PubMed ID: 32221155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Oguri T; Yoshida T; Shimizu J; Horio Y; Hata A; Kaji R; Fujita S; Sekido Y; Kodaira T; Kokubo M; Katakami N; Yatabe Y
    J Thorac Oncol; 2015 Dec; 10(12):1720-5. PubMed ID: 26743855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK Mutation Status in EGFR-negative Non-small-cell Lung Cancer Patients in Bulgaria.
    Djambazov SN; Vekov TY; Mekov EV; Slavchev GS; Petkov RE; Kostadinov DT; Konteva LT
    Folia Med (Plovdiv); 2018 Sep; 60(3):397-401. PubMed ID: 30355843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma.
    Yin K; Feng HB; Li LL; Chen Y; Xie Z; Lv ZY; Guo WB; Lu DX; Yang XN; Yan WQ; Wu YL; Zhang XC
    Thorac Cancer; 2020 Feb; 11(2):346-352. PubMed ID: 31794146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with
    Oya Y; Kuroda H; Nakada T; Takahashi Y; Sakakura N; Hida T
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy.
    Park SE; Noh JM; Kim YJ; Lee HS; Cho JH; Lim SW; Ahn YC; Pyo H; Choi YL; Han J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Res Treat; 2019 Apr; 51(2):493-501. PubMed ID: 29914238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
    Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.